Related Experiment Video
Updated: Jun 22, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction
1Simcyp Limited, John Street, Sheffield, UK. l.almond@simcyp.com
Abstract:
Although CYP induction is not generally considered to be as clinically relevant as CYP inhibition, there are important examples where induction has caused both therapeutic failure, due to insufficient exposure to parent drug, and toxicity, mediated by increased formation of reactive metabolites. Furthermore, while there has been considerable progress in the extrapolation of in vitro data to predict the in vivo consequences of enzyme inhibition, less attention has been given to the quantitative impact of enzyme induction as a mechanism of drug-drug interaction (DDI) and as a component of compound selection and early drug development. We discuss current approaches in the context of a mechanistic framework for the prediction of the extent and time-course of enzyme induction in vivo based on in vitro experimentation. Factors influencing the extent of DDI due to CYP induction are summarised, and areas deficient in information that would allow more accurate prediction within target populations are highlighted.
Insights
Cytochrome P450 (CYP) induction can lead to therapeutic failure and toxicity. More research is needed to predict CYP induction drug-drug interactions (DDIs) from in vitro data for better drug development.
Area of Science:
- Pharmacology
- Drug Metabolism
- Medicinal Chemistry
Background:
- Cytochrome P450 (CYP) enzyme induction is a significant, yet often underestimated, cause of drug-drug interactions (DDIs).
- CYP induction can result in therapeutic failure by reducing parent drug exposure and toxicity through increased reactive metabolite formation.
- Current methods for predicting in vivo consequences of CYP inhibition are more advanced than those for CYP induction.
Purpose of the Study:
- To review current approaches for predicting the impact of CYP enzyme induction.
- To highlight the need for better quantitative prediction of CYP induction DDIs.
- To identify knowledge gaps in predicting CYP induction in specific populations.
Main Methods:
- Discussion of current methodologies for predicting CYP induction.
- Analysis of factors influencing the extent of DDIs caused by CYP induction.
- Review of in vitro to in vivo extrapolation techniques for enzyme induction.
Main Results:
- CYP induction poses significant clinical risks, including therapeutic failure and toxicity.
- There is a need for improved quantitative prediction of CYP induction-mediated DDIs.
- Gaps exist in predicting CYP induction effects in target populations.
Conclusions:
- Accurate prediction of CYP induction is crucial for successful drug development and patient safety.
- Further research is required to refine in vitro-to-in vivo extrapolation for CYP induction.
- Addressing knowledge gaps will improve the management of CYP induction DDIs.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Quantitative Aspects of Drug-Receptor Interaction
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Drug toxicity: Idiosyncratic Reactions
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Drug Metabolism: Phase I Reactions
